Výsledky vyhledávání - "Miklos Salgo"

Primary Source

Nomination of Nicolas Miklos Salgo To Be United States Ambassador to Sweden June 16, 1992.

Publikováno v: American Reference Library - Primary Source Documents; 2001, p1, 0p

Primary Source

Nomination of Nicolas Miklos Salgo for the Rank of Ambassador While Serving as Special Negotiator for Property Issues July 19, 1989.

Publikováno v: American Reference Library - Primary Source Documents; 2001, p1, 0p

Zobrazit plný text záznamu

Switching from a Toxicity-Causing Antiretroviral to Enfuvirtide in Patients with HIV: The SWITCH TOX Study

Autor: Miguel Górgolas, Schlomo Staszewski, Lucy Rowell, Piotr Pulik, Joaquin Portilla, Adrian Streinu-Cercel, Wulf Böcher, Sorin Rugină, Matthias Stoll, Miklos Salgo, Markus Müller

Publikováno v: HIV Clinical Trials. 9:375-386

Treatment-related toxicities frequently limit antiretroviral therapy for patients with HIV-1 infection. This study evaluated the changes in treatment-limiting toxicities when the primary toxicity-causing agent was replaced with enfuvirtide.Adult pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cab24cf38840ce86cbcbf514448fb2e7
https://doi.org/10.1310/hct0906-375

Zobrazit plný text záznamu

Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients

Autor: David Wright, Ralph DeMasi, Anna Shikhman, Jain Chung, Neil M.H. Graham, Emily Labriola-Tompkins, Yu Yuan Chiu, Allen E. Rodriguez, Ernestine Tucker, Sharon Walmsley, Lucille Donatacci, Lucy Rowell, Miklos Salgo, Eliot Godofsky

Publikováno v: HIV Clinical Trials. 9:73-82

To evaluate the safety and antiviral activity of once-daily (qd) enfuvirtide (ENF) compared with twice daily (bid) ENF.T20-401 was a phase 2, open-label, randomized, 48-week pilot study comparing ENF 180 mg qd versus ENF 90 mg bid, added to an optimi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef4e8b8adf25dafbab88af32ebb20e45
https://doi.org/10.1310/hct0902-73

Zobrazit plný text záznamu

Characterization of Envelope Glycoprotein gp41 Genotype and Phenotypic Susceptibility to Enfuvirtide at Baseline and on Treatment in the Phase III Clinical Trials TORO-1 and TORO-2

Autor: Tom Melby, Prakash R. Sista, N. Roberts, Gabrielle Heilek-Snyder, T J Matthews, T. Kirkland, Michael L. Greenberg, Ralph DeMasi, Miklos Salgo, Nick Cammack

Publikováno v: AIDS Research and Human Retroviruses. 22:375-385

Enfuvirtide (T-20) is the first entry inhibitor approved for treatment of HIV infection and acts by inhibiting conformational changes in the viral envelope protein gp41 that are necessary for fusion of the virus and host cell membranes. Here we prese

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5d8b8cd716ccf5629c14fa3104db5cd
https://doi.org/10.1089/aid.2006.22.375

Zobrazit plný text záznamu

Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) Trials

Autor: Christine Katlama, Jain Chung, François Raffi, Miklos Salgo, Lynn M. Smiley, Martin Wilkinson, Michael S. Saag

Publikováno v: Clinical Infectious Diseases. 42:870-877

Background. Early virological response to antiretroviral therapy is predictive of long-term treatment outcome in therapy-naive patients. In treatment-experienced patients, such correlations are less well defined, because initial responses may be less

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b01cce6b7f8f2805679259ee2f5f38c
https://doi.org/10.1086/500206

Zobrazit plný text záznamu

Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 Disease

Autor: Zarina Gafoor, Jain Chung, Denise Guimaraes, Julio S. G. Montaner, Miklos Salgo, Ralph DeMasi

Publikováno v: HIV Clinical Trials. 6:281-290

Determinants of therapeutic success are poorly characterized in patients with extensive HAART experience. Positive prognostic factors (PPFs) in the TORO trials could serve as the basis for a prognostically meaningful staging of treatment-experienced

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c2d53764761d836380f479cbfa6524
https://doi.org/10.1310/0xh7-f2v2-1k0r-nu2w

Zobrazit plný text záznamu

Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro

Autor: S. Janumpalli, T J Matthews, Tom Melby, S. M. Mosier, J. Erickson, D. Lambert, D. Davison, Miklos Salgo, S. A. Stanfield-Oakley, Nick Cammack, M. Mink, Prakash Sista, Lei Jin, Michael L. Greenberg

Publikováno v: Journal of Virology. 79:12447-12454

Enfuvirtide (ENF), a novel human immunodeficiency virus type 1 (HIV-1) fusion inhibitor, has potent antiviral activity against HIV-1 both in vitro and in vivo. Resistance to ENF observed after in vitro passaging was associated with changes in a three

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0db43009c0068ae530ceb44a5c726d9
https://doi.org/10.1128/jvi.79.19.12447-12454.2005

Zobrazit plný text záznamu

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

Autor: Mike Mink, Thomas J. Matthews, Donna K. Davison, Sarah M. Mosier, Ralph DeMasi, Lei Jin, Prakash Sista, Emily L. Nelson, Nick Cammack, Miklos Salgo, Michael L. Greenberg, Tom Melby

Publikováno v: AIDS. 18:1787-1794

Enfuvirtide (ENF) is the first of a novel class of drugs that block HIV gp41-mediated viral fusion to host cells. Viruses with mutations at positions 36-38 in HIV-1 gp41 and/or reduced susceptibility to ENF have been selected both in vitro and in viv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a69aef78817afc9a2aa21433d34fa6b2
https://doi.org/10.1097/00002030-200409030-00007

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání